Kairos Pharma Ltd. (KAPA)

Overview

Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company engaged in the development of innovative therapeutics for cancer patients. With a focus on addressing unmet medical needs, the company is dedicated to the research and development of treatments for various types of cancer, including prostate, lung, breast, and glioblastoma. Originally known as NanoGB13, Inc., the company underwent a rebranding to Kairos Pharma, Ltd. in July 2016 to better reflect its broader focus on cancer therapeutics. Founded in 2013 and headquartered in Los Angeles, California, Kairos Pharma has established itself as a dynamic entity in the biopharmaceutical sector, leveraging both cutting-edge technology and scientific expertise to develop treatments that aim to improve survival rates and quality of life for cancer patients.

Products and Services

• Antibodies for Cancer Treatment:

  Kairos Pharma is at the forefront of developing targeted antibodies designed to attack cancer cells without harming normal cells. These antibodies are engineered to recognize specific proteins found on the surface of cancer cells, thereby enabling a focused and potent therapeutic effect. This approach holds promise for significantly reducing side effects compared to traditional chemotherapy and radiation treatment options.

• Small Molecules for Cancer Treatment:

  The company's portfolio also includes small molecule drugs that target specific pathways critical to cancer cell growth and survival. These small molecules are designed to interfere with the processes cancer cells need to proliferate, thereby halting the progression of the disease. Kairos Pharma's research in this area aims to provide patients with effective, less toxic treatment alternatives, potentially improving outcomes in the fight against cancer.